Trump Administration Reclassifies Medical Marijuana to Schedule III
Cover image from csmonitor.com, which was analyzed for this article
Acting AG Blanche moves state-licensed medical marijuana to Schedule III like ketamine, signaling reform path. Public opinion mixed on reduced dangers. Ties into broader FDA red tape cuts for drugs like ibogaine aiding veterans.
PoliticalOS
Friday, April 24, 2026 — Politics
The Trump administration has formally recognized currently accepted medical uses for state-regulated marijuana by moving it to Schedule III, removing a longstanding tax penalty and lowering research barriers while stopping short of federal legalization. The move rests on a 2023 HHS evidence review yet faces legal challenges and coexists with persistent worries about cannabis-use disorder, youth access and blurred medical-recreational lines. Paired with a separate push to accelerate psychedelic therapies such as ibogaine for veterans, the policy signals a broader reevaluation of once-forbidden substances; the decisive test will be whether ensuing research validates therapeutic claims or confirms long-term societal costs.
What outlets missed
Most outlets underplayed the 2023 HHS evaluation that provided the scientific backbone for rescheduling, documenting currently accepted medical use through state programs and comparative abuse potential lower than Schedules I and II. The precise tax mechanism — repeal of IRC Section 280E restrictions for Schedule III entities — received scant detail despite its estimated annual value to the industry in the hundreds of millions. Coverage of the ibogaine executive order rarely noted that the Stanford trial was small, open-label and run abroad, nor did most reports clarify that the marijuana order and psychedelic directive are separate though philosophically linked actions. State counts were occasionally imprecise; only Idaho maintains a complete prohibition on all cannabis products, while Kansas permits low-THC medical use. Finally, few stories examined how the June 29 DEA hearing could extend Schedule III benefits to recreational programs, an outcome that would amplify both the fiscal upside and the public-health debate.
You've seen the spin. Now read what happened.
The unbiased version strips away everything the other four added: the framing, the omissions, the selective emphasis. Just what happened.
Read all five, free for 7 days$4.99/mo after trial. Cancel anytime.